Our radio-oncology activities
Let’s fight to create a cancer-free world
Debiopharm seeks to stay on the cutting edge of cancer research by identifying innovative therapeutic options that have the potential to help cancer patients to achieve and remain in remission. Today we know that tumor cells have multiple mechanisms that work to promote survival, mutation and replication. We believe that with enough research and understanding, we can find the key to a cure, starting a journey towards a cancer-free world.
What better way to fight cancer than to use the world as our laboratory? That is why we evaluate discovery and early stage oncology therapies from around the globe in order to in-license for further clinical development. Over the years, our drug development activity takes compounds closer to regulatory approval, offering potential commercial pharmaceutical partners added value and reduced risk.
Currently we have 11 cancer therapies in our pipeline, undergoing clinical research from Phase I to Phase III. Today our pipeline includes a variety of treatment modalities including an anti-CD37 antibody-drug conjugate, naratuximab emtansine (Debio 1562), a CCK2R peptide receptor radionuclide therapy Debio 1124 and an antagonist of IAPs (Inhibitor of apopstosis protein), Debio 1143.
Naratuximab emtansine (Debio 1562)
Anti-CD37 Antibody Drug Conjugate
Naratuximab emtansine is a first-in-class anti-CD37 ADC demonstrating strong synergy with anti-CD20 antibodies in vivo, revealing a clinically relevant and actionable therapeutic class for further evaluation for NHL patients. The compound is an investigational treatment for patients with B-cell malignancies that securely delivers a cytotoxic payload by specifically targeting CD37 antigen widely found on B cell surfaces. The product is currently in phase IIb in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status.
Debio 1124 is a theranostic (therapeutic and diagnostic) radiotherapy that can be used both as a sensitive diagnostic tool during an initial imaging step, and a targeted treatment for patients having tumors whose characteristics show the potential to benefit from therapy. The compound is a radioconjugated minigastrin analogue designed to target the CholeCystoKinin 2 Receptor (CCK2R) expressed in certain tumors. The compound is being developed to treat cancers that express CCK2R receptor, including Medullary Thyroid Cancer (MTC) and other solid tumors.
Antagonist of IAPs
Debio 1143 is the most clinically advanced antagonist of IAPs (inhibitor of apoptosis proteins). The compound works by sensitizing tumor cells to radio-chemo therapy, promoting programmed cell death and fostering anti-tumor immunity. The FDA granted Breakthrough Therapy Designation status based on the clinical benefit observed in the treatment of patients with confirmed diagnosis of previously untreated, unresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in combination with current standard of care, cisplatin-based concomitant standard fractionation chemoradiation therapy (CRT). Currently poised to enter into a Phase III, pivotal trial later this year in combination with CRT in Head & Neck cancer, the compound is also being investigated along with immune checkpoint inhibitors (PD-1/PD-L1) in various solid tumors.